Introduction {#S0001}
============

Neuroendocrine neoplasms (NENs) are relatively rare and heterogeneous malignancies originating from cells of the diffuse neuroendocrine system, widely dispersed in the body. They comprise a wide range of grade of malignancy, from very indolent to rapidly proliferative. By extrapolating from the gastroenteropancreatic (GEP) tract terminology more in general the well-differentiated (WD) NENs can be named tumors (NETs) whereas the poorly differentiated (PD) are carcinomas (NECs) also in the lung.

In accordance with the 2015 WHO lung NEN classification lung NETs represent the low/intermediate grade by comprising typical (T) and atypical carcinoids (AC) whereas large cells and small cells lung NECs are the high-grade forms.[@CIT0001]

Depending on symptoms due to the hypersecretion of hormones/amines by the tumor, lung NETs can be distinguished in functioning or non-functioning. The carcinoid syndrome is the most common clinical syndrome associated with a lung NET.[@CIT0002],[@CIT0003]

Lung NETs are usually managed similarly to GEP NETs. However while in GEP NETs several new treatments have been approved over the last years, everolimus (EVE) is the only drug ever approved by FDA/EMA specifically for lung NETs. However other drugs can be used in clinical practice despite they were not specifically approved for lung NETs, including somatostatin analogues (SSAs), chemotherapy, liver-directed treatments. Furthermore other therapies can be proposed within clinical trials, such as peptide receptor radionuclide therapy (PRRT).

In this review, we had focussed on clinical and biological features of advanced NETs of the lung treated with EVE.

Materials and Methods {#S0002}
=====================

Identification {#S0002-S2001}
--------------

A comprehensive literature search was designed and conducted by an experienced medical librarian with input from the study investigators. We searched the electronic databases Ovid MEDLINE, Embase and Scopus. Various combinations of database-specific controlled vocabulary (subject headings) were used, supplemented by keywords, title and abstract terms for the concepts and synonyms relating to neuroendocrine tumor, neuroendocrine tumors, neuroendocrine tumor, neuroendocrine tumors, neuroendocrine neoplasm, neuroendocrine neoplasms, carcinoid tumor or carcinoid tumors and lung, pulmonary, bronchopulmonary, broncho-pulmonary or bronchial and everolimus, rad001, m-tor inhibitor, m-tor inhibitors, mammalian target of rapamycin inhibitor or mammalian target of rapamycin inhibitors. Last updated literature search was performed on December 30th, 2019.

Screening {#S0002-S2002}
---------

Literature search results in records. Record screening was performed in order to include patients with advanced well-differentiated pulmonary NETs treated with EVE. Review articles, preclinical studies and book chapters were excluded. English language restriction was applied.

Eligibility {#S0002-S2003}
-----------

Eligible studies were selected by reviewing the full-text articles.

Studies including advanced pulmonary NETs receiving EVE with palliative intent were eligible.

Studies exploring the role of EVE in combination with other therapies such as with PRRT, chemotherapy, SSA, interferon (IFN) or local therapies were considered eligible.

Studies exploring the role of other therapies such as PRRT, chemotherapy or SSA or IFN without EVE were considered ineligible.

Studies were required to report tumor response and survival data.

Length of follow-up should be more than 3 months.

Prospective clinical trials and retrospective analysis of prospective trials were eligible; clinical trials or case series with less than 10 patients were excluded. If results were given for a population of mixed poorly and well-differentiated NETs, these studies were excluded. Patients treated with adjuvant intent were not included in the qualitative synthesis.

Qualitative Description {#S0002-S2004}
-----------------------

Clinical and methodological data were extracted from the eligible studies.

Details of the study design, therapy regimen, prior therapies, histological typing, patient characteristics, side effects ad length of follow-up were collected.

The Biological Landscape of Neuroendocrine Tumor of the Lung {#S0003}
============================================================

Pathologic and Phenotypic Features {#S0003-S2001}
----------------------------------

Lung NETs show the neuroendocrine (NE) morphology and derive from the mature cells of the pulmonary diffuse NE system.[@CIT0004],[@CIT0005]

Mitoses and necrosis are essential for classifying TC and AC.[@CIT0001] Immunohistochemistry can be very helpful considering its constant positive staining for cytokeratin, neuroendocrine markers as chromogranin A (CgA), synaptophysin (SYN) and neuron-specific enolase (NSE).[@CIT0006]

The Ki-67 is not necessary to classify lung NETs but its level can be useful in distinguishing between WD and PD forms, especially in limited diagnostic material,[@CIT0001],[@CIT0007],[@CIT0008] and it could have a prognostic role.[@CIT0009]--[@CIT0013]

The functional expression of somatostatin receptors (SSTRs) is usually detected through a positron emission tomography/computed tomography (PET/CT) with[@CIT0068] Ga-DOTA-peptide or, if not available, a somatostatin receptor scintigraphy (SRS).[@CIT0014] These nuclear medicine techniques play an important role in the staging,[@CIT0015],[@CIT0016] detection of recurrence,[@CIT0017] prediction of the response to PRRT,[@CIT0018] prediction of positive prognosis,[@CIT0019] therefore lead to a better clinical management.[@CIT0020],[@CIT0021]

By contrast, the value of PET/CT with ^18^F-fluorodeoxyglucose (FDG) is still controversial. Some studies reported that the standardized uptake value is generally higher in AC, demonstrating that FDG PET is helpful in predicting the behaviour of lung NETs.[@CIT0022]--[@CIT0025]

Evidence about the clinical utility of circulating biomarkers in lung NET is lacking. Despite the low specificity and the very poor level of evidence, plasma chromogranin A (CgA) in lung NET is the most used marker at baseline and in the follow-up.[@CIT0002],[@CIT0026] Elevated level of plasma CgA is usually associated with an advanced disease and with indolent disease.[@CIT0027],[@CIT0028] Novel markers, such as circulating tumor DNA, circulating tumor cells, circulating miRNAs and measurements of multianalyte transcript analysis appear to represent the most promising strategy in lung NET.[@CIT0026]

Epidemiologic and Clinical Features {#S0003-S2002}
-----------------------------------

Compared with lung NECs lung NETs occur predominantly in female, younger and non-smoker patients and they have a better prognosis.[@CIT0002],[@CIT0029]

Typical carcinoid is ten times more common than AC and develops metastatic lesions in up to 15% of cases with a median time to recurrence of 4 years. Atypical carcinoid is metastatic in up to one half of cases with a median time to recurrence of 1.8 years.[@CIT0002]

Synchronous metastases are present in 28% of lung NET patients,[@CIT0030] and metachronous metastases may develop even many years after surgical removal of the primary tumor and regional nodes,[@CIT0030]--[@CIT0034] hence justifying a long-term surveillance even up to 15 years.[@CIT0002],[@CIT0035],[@CIT0036]

Metastases usually occur in regional lymph nodes but also distantly to the liver, bones, lung, distant lymph node and subcutis.[@CIT0027],[@CIT0032],[@CIT0037]

Although lung NETs are usually slow-growing malignancies, the prognosis of distant metastases disease is relatively poor. However metastatic survival data are lacking and have been mainly extracted from SEER database analysis[@CIT0030],[@CIT0036] and retrospective analyses.[@CIT0032],[@CIT0038],[@CIT0039]

Moreover most of survival data have been collected considering the whole stage population (localized, regional, and distant metastatic) or have been extracted from surgical databases.[@CIT0040]--[@CIT0044]

The latest ESMO guidelines summarize these data reporting that TC patients have a 5-year survival rate of 87--90%, much higher than that of AC, that is 44--78%.[@CIT0035]

Median survival from diagnosis of advanced lung NET patients is 6--7 years, as reported in three retrospective studies.[@CIT0027],[@CIT0032],[@CIT0045]

Several prognostic factors have been associated with poor survival in the metastatic setting, however more efforts should be made to identify univocal results and consequently improve patient selection. To date several independent clinical prognostic factors were described, such as age, poor ECOG PS, histotype, tumor size, symptoms, high CgA levels, negative SRS, presence of bone metastasis, liver metastasis, Ki-67 as a continuous variable and lower time to relapse.[@CIT0027],[@CIT0032],[@CIT0041],[@CIT0044],[@CIT0046]

Rationale of mTOR Inhibitors in Lung NETs {#S0003-S2003}
-----------------------------------------

Lung NETs present a few genetic abnormalities compared with NECs, especially regarding chromatin-remodelling genes and DNA repair pathways.[@CIT0047]--[@CIT0049] The most frequently mutated somatic genes are reported in [Table 1](#T0001){ref-type="table"}.Table 1Somatically Mutated Gene in Lung Neuroendocrine TumorsMutated GeneSignificance of the Molecular AlterationsMEN-1^ ^[@CIT0047]--[@CIT0049]Gene that products Menin, a protein that interacts with chromatin-associated protein complexes and also regulates some non-coding RNAs, participating in epigenetic control mechanismsE3-Ub ligases[@CIT0047]Gene involved in Protein ubiquitination as posttranslational modificationARID family[@CIT0047],[@CIT0049]Genes involved in the SWI--SNF complex and chromatin remodelingKMT2 family[@CIT0047],[@CIT0048]Genes involved in covalent histone modification/chromatin remodelingSMARCA4[@CIT0047]Genes involved in chromatin remodelingHNF1A[@CIT0047]Gene that regulated the expression of acute phase proteins and interleukin 1 receptor, which are involved with inflammation and might play a possible tumor suppressor roleFOXA3[@CIT0047]Genes involved in covalent histone modification/chromatin remodelingPSIP1[@CIT0049]Genes involved in chromatin remodelingPI3K/AKT/mTOR pathway[@CIT0048]Pathway involved in intracellular signaling pathway important in regulating the cell cycle

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase and is the catalytic subunit of two functionally distinct multiprotein complexes, mTOR complex 1 (mTORC1) and 2 (mTORC2).

The mTOR is activated via phosphorylation, following activation of an upstream signaling cascade, the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway, that is important in regulating the cell cycle.

Everolimus, also known as RAD001, is an oral derivative of rapamycin, which has shown a potent inhibitory activity of the mTORC1 in primary cultures of human NET[@CIT0050] and proven efficacy in lung NETs. Lung NETs exhibit genetic abnormalities located in the PI3K/AKT/mTOR pathway causing the upregulation of mTOR signaling components or downregulation of its upstream negative regulators.[@CIT0048],[@CIT0051]-[@CIT0053]

Furthermore, deregulation of PI3K and loss of function of PTEN can predict response to mTOR inhibitors[@CIT0054]--[@CIT0056] and lower level of mTOR, p70S6K and Akt were described as potential predictive markers of resistance.[@CIT0051],[@CIT0057]

Considering the overexpression of pro-angiogenic molecules and of tyrosine kinase receptors (TKRs), the rationale of EVE in lung NET is also based on its involvement in angiogenesis process (regulating the activity of hypoxia-inducible factor alpha, HIF-α, and the expression of VEGF and PDGF-b)[@CIT0058] and in tyrosine kinase activation (EGFR, IGFR and FGFR-3).

Clinical Evaluation of Everolimus Treatment in Neuroendocrine Tumor of the Lung {#S0004}
===============================================================================

Results of Literature Review {#S0004-S2001}
----------------------------

Records identified through literature search were 610:123 from MEDLINE searching, 357 from Embase and 130 from Scopus.

The total number of manuscripts screened was 97.

On the basis of the aforementioned criteria of selection, eligible studies included in the final analysis were 6 ([Table 2](#T0002){ref-type="table"}, [[Supplementary Figure 1](http://www.dovepress.com/get_supplementary_file.php?f=249928.doc)]{.ul}).[@CIT0059]--[@CIT0065]Table 2Key Characteristics of Eligible StudiesStudy, Phase, First Author (Year)TreatmentPrimary SiteLung NET (n)/Patients EnrolledLung NET Treated with Eve (n)Line of TherapyAssociation with SSARADIANT-2, Phase III\
Pavel ME (2011)[@CIT0059]EVE 10 mg + OCT LAR 30 mg or placebo + OCT LAR 30 mgMixed NET44/42933ANYYES (100%) (OCT LAR 30mg q28)Lung subgroup analysis RADIANT-2, phase III\
Fazio N (2013)[@CIT0060]EVE 10 mg + OCT LAR 30 mg or placebo + OCT LAR 30 mgLung NET44/42933ANYYES (100%) (OCT LAR 30mg q28)RADIANT-4, phase III\
Yao JC (2015)[@CIT0061]EVE 10 mg or placeboMixed NET90/30263ANY\
(1L 39%)0%Lung subgroup analysis RADIANT-4, phase III\
Fazio N (2017)[@CIT0062]EVE 10 mg or placeboLung NET90/30263ANY\
(1L 14 vs 11)0%ITMO,\
Phase II\
Bajetta E (2014)[@CIT0063]EVE 10 mg + OCT LAR 30 mgMixed NET11/5011FIRSTYES (100%) (OCT LAR 30mg q28)LUNA,\
Phase II\
Ferolla (2017)[@CIT0065]PAS or EVE 10 mg or combinationLung and thymus NET116/124781L (%): 29 vs 36 vs 32Only the combination arm (EVE+PAS)[^1]

All but one included thoracic and extra-thoracic populations. Three were randomised controlled trials (RCTs), two Phase III and one Phase II. The LUNA trial was the only one specifically designed for patients with advanced lung/thymic NETs. It was a three-arm randomised Phase II trial comparing Pasireotide (PAS) with everolimus (EVE) with both. The other two randomised trials were double-arm placebo-controlled phase III randomised trials: the RADIANT-2 for patients with carcinoid syndrome-associated NETs from any origin and RADIANT-4 for non-functioning non-pancreatic gastrointestinal and lung NETs.

Finally, the ITMO study was a prospective single-arm phase II and two studies were post hoc retrospective analyses from the RADIANT-2 and RADIANT-4.

Overall, 185 patients with lung NET received EVE within prospective trials ([Table 3](#T0003){ref-type="table"})Table 3Characteristics of Lung NET Patients Treated with EVE Included in the Eligible StudiesStudyLung NET Treated with EVE (n)EVE Single Agent or ComboTC (%)AC (%)NOS (%)Criteria InclusionCriteria StratificationMedian Age (Range)Male (%)Caucasian (%)PS=0 (%)Liver mts (%)Prior SSA (%)Prior cht (%)Prior RT (%)Functioning Disease (%)Elevated CgA at EntryLung subgroup analysis RADIANT-233+ OCT LAR76186-Carcinoid syndrome\
-Any line\
-Baseline PDNR60 (22--83) (general population)60.6NR45.592 (general population)6739NR1001279 (median value)Lung subgroup analysis RADIANT-463Single agent35758- Grade 1--2 (KI67 \<20%)\
\[WHO 2010\]\
-No syndrome\
-Any line\
-Baseline PDPrevious SSA, tumor origin, PS67 (34--86)51847368.3433940046% (general population)ITMO11+ OCT LARNRNRNR-TC and AC \[WHO 2004\]\
- First lineNR58 (25--76)\
(general population)58\
(general population)100100NR00026\
(general population)76%\
(general population)LUNA83 (of whom 78 lung NET)42 single agent29710- TC and AC \[WHO 2004\]\
-Any line\
-Baseline PD\
-No severe syndromeTC vs AC and first line vs others66 (61--73)5510057814540.52617NR41 PAS LAR3268061 (56--69)689866764658.519.522NR[^2]

Patient Selection {#S0004-S2002}
-----------------

The inclusion criteria differed from study to study.

The RADIANT-2 enrolled only NETs associated with a carcinoid syndrome, from any primary site. The Ki-67 was not required as an inclusion criterion. Prior therapies were allowed. Neither stratification nor pre-planned analysis for lung NETs were included in the design of the trial. Radiologic baseline progressive disease within the last 12 months, not necessarily RECIST-based, was required. With regards to the carcinoid syndrome inclusion criteria reported "history of symptoms attributed to carcinoid syndrome (flushing, diarrhea, or both)".

The RADIANT-4 included only non-functioning NETs, from GI or lung, with up to 20% Ki-67 (grade 1 or grade 2 in accordance with the WHO 2010 classification). Previous treatments were allowed. Radiologic baseline progressive disease within the last 6 months, not necessarily RECIST-based, was required.

While in the RADIANT-2 no stratification was planned for lung NETs, a prognostic stratification into two subgroups was decided in the RADIANT-4, by including lung NETs into the poor prognosis category, together with stomach, colon and rectum.

The ITMO study included just therapy-naïve (a true first-line) mixed population well differentiated, G1-2, NETs. No specific analysis for lung NETs was pre-planned.

While in the aforementioned trials lung NETs could be included regardless of their definition of TC or AC, in the LUNA trial all included lung NETs had to be defined as TC or AC. The LUNA required a radiologic baseline progressive disease within the last 12 months, not necessarily RECIST-based. Patients with severe functioning disease requiring symptomatic treatment with SSA were ineligible and stratification was performed according to histology (TC versus AC) and to line of study treatment (first line of systemic medical treatment versus other).

No specific inclusion criteria regarded tumor burden in any trials.

Efficacy Data {#S0004-S2003}
-------------

Primary endpoints were progression-free survival (PFS) by central radiology review for the RADIANT-2 trial, PFS by real-time central radiology review for the RADIANT-4, 9-month PFS rate for the LUNA trial and overall response rate (ORR) for the ITMO study.

While RADIANT-4 and LUNA were positive studies according to their met statistical goal, RADIANT-2 was a negative study due to the unmet pre-specified threshold of p=0.024.

No statistical significant improvement of OS was reported so far in favor of EVE from the two phase III RCTs.

[Table 4](#T0004){ref-type="table"} comprises all the efficacy data of the selected studies.Table 4Efficacy Outcomes of Eligible StudiesStudyTreatmentLung NET (n)PR %DCR %Tumor Shrinkage (%)mPFS (m)HRM-fu (m)Lung subgroup analysis RADIANT-2EVE 10 mg + OCT LAR 30 mg or placebo + OCT LAR 30 mg440 vs 0NR67 vs 2713.63 vs 5.590.72NRLung subgroup analysis RADIANT-4EVE 10 mg or placebo902 vs 481 vs 5958 vs 139.2 vs 3.60.50NRITMO 5-Year UpdateEVE 10 mg + OCT LAR 30 mg119 (lung NET)92 (general population)\*\*NR33.6 (general population)NR50 (general population)LUNAPAS or EVE 10 mg or combination1162.4 vs 2.4 vs 2.4\*36.5 vs 33.4 vs 51.2\*31 vs 49 vs 738.5 vs 12.5 vs 11.8NR12[^3][^4]

Special Consideration: Which Tumor Population {#S0004-S2004}
---------------------------------------------

Median age (58--67 years), males (51--68%), Caucasians (84--100%) and WHO PS score of 0 (45.5--75%) were similar from all the studies, except for ITMO study that enrolled only patients with PS of 0.

Among the patients in whom tumor morphology was reported, the majority were TC, except for LUNA trial that selected a more aggressive tumor population.

The EVE-arm included lung NETs who had mainly been previously treated with other therapies whereas the rate of first-line treatment was 14--36%.

Prior SSA therapy was administered in 43--46% of EVE treated population (except for RADIANT-2 trial that enrolled a higher percentage (67%) of patients previously treated with SSA).

Radiotherapy, including PRRT, had been received before EVE in 19.5--40% of patients.

The tumor burden of lung NET treated with EVE was described as presence of metastatic hepatic lesions (ranging from 68% to 81%) and elevated level of CgA (76% of cases in ITMO trial and 1278.8 ng/mL as median value in RADIANT-2).

Apart from RADIANT-2 and −4, the others studies included patients with syndrome ranging from 17% to 29%.

[Table 5](#T0005){ref-type="table"} comprises all the toxicities reported in the selected studies.Table 5Grade 3 or 4 Everolimus-Adverse Events Occurred in Eligible StudiesLung Subgroup Analysis RADIANT-2 EVE Plus OCT LARLung Subgroup Analysis RADIANT-4 EVEITMO EVE Plus OCTITMO 5-Year Update EVE Plus OCTLUNA EVELUNA EVE Plus PASStomatitis23 (69.7%)7 (11.3%)5 (10%)4 (8%)4 (10%)2 (5%)Rash11 (33.3%)01 (2%)1 (2%)3 (7%)NRFatigue4 (12.1%)2 (3.2%)NRNR1 (2%)4 (10%)Diarrhoea9 (27.3%)3 (4.8%)11 (22%)4 (8%)3 (7%)8 (19%)Nausea4 (12.1%)2 (3.2%)NRNR1 (2%)NRInfectionsNR5 (7.1%)1 (2%)NRNRNRDysgeusia4 (12.1%)0NRNR0NRAnaemia5 (15.2%)2 (3.2%)1 (2%)1 (2%)1 (2%)2 (5%)Leukopenia4 (12.1%)NR1 (2%)1 (2%)NRNRDecreased weight4 (12.1%)1 (1.6%)NRNR1 (2%)3 (7%)Thrombocytopenia6 (18.2%)NRNRNR1 (2%)NRDecreased appetite4 (12.1%)0NRNR2 (5%)2 (5%)Peripheral oedemaNR2 (3.2%)NRNR1 (2%)1 (2%)Hyperglycaemia5 (15.2%)6 (9.8%)NRNR7 (17%)10 (24%)Dyspnoea5 (15.2%)1 (1.6%)NRNR2 (5%)2 (5%)Pulmonary eventsNR1 (1. 6%)NRNR3 (7%)2 (5%)VomitingNRNRNRNRNR1 (2%)Pruritus4 (12.1%)1 (1.6%)NRNRNRNRAsthenia8 (24.2%)1 (1.6%)NRNR1 (2%)1 (2%)Erythema5 (15.2%)NRNRNRNRNRPyrexiaNR2 (3.2%)NRNR1 (2%)NRHypercholesterolemiaNRNRNR1 (2%)NRNRHypokalemiaNRNRNR4 (8%)NRNRHypertriglyceridemiaNRNRNR1 (2%)NR1 (2%)HyponatremiaNRNRNR1 (2%)NRNRAcute myocardial infarctionNRNRNR1 (2%)NRNRConstipationNRNRNRNR1 (2%)NRBlood alkaline phosphatase increasedNRNRNRNR1 (2%)1 (2%)γ-glutamyltransferase increasedNRNRNRNR3 (7%)3 (7%)HypophosphataemiaNRNRNRNR2 (5%)1 (2%)Mouth ulcerationNRNRNRNR1 (2%)1 (2%)HaemorrhoidsNRNRNRNR1 (2%)NRFlushingNRNRNRNR1 (2%)NRDiabetes mellitusNRNRNRNRNR3 (7%)Chest painNRNRNRNRNR1 (2%)Aspartate aminotransferase increasedNRNRNRNRNR1 (2%)DysphagiaNRNRNRNR2 (5%)NRGeneral physical health deteriorationNRNRNRNR1 (2%)NRPulmonary embolismNRNRNRNR1 (2%)2 (5%)[^5]

Special Consideration: Which Biomarker {#S0004-S2005}
--------------------------------------

A recent study analyzed genomic profiling on tumor samples along with nongenomic biomarkers, including circulating CgA and NSE levels, from patients enrolled in the RADIANT-2, RADIANT-3 and RADIANT-4. Lung NET patients showed a significant correlation between PFS and chromosomal aberrations, in particular LOH in chromosome 3. This correlation was still significant after adjusting for tumor grade and baseline circulating levels of CgA and NSE.[@CIT0066]

Studies selected in this review did not assess the potential prognostic or predictive role of soluble angiogenic biomarkers (VEGFR1, PIGF), as performed in the RADIANT-3 in the advanced pancreatic NET population.[@CIT0067] In a recent study[@CIT0068] higher baseline neutrophil-lymphocyte ratio (NLR) and lower (lymphocyte-monocyte ratio) LMR correlate with a shorter PFS in patients treated with EVE in NET population of the RADIANT-3 and RADIANT-4 trials. However in the lung subgroup analysis there was no trend observed, possibly due to the small number of patients in the group. A blood mRNA-based biomarker, the NETest, has been proposed as a multianalyte algorithmic tool for lung NET and may represent a promising strategy to establish a diagnosis and monitor therapeutic efficacy.[@CIT0069]

Special Consideration: Which Timing for EVE {#S0004-S2006}
-------------------------------------------

A post hoc analysis of the RADIANT-4 reported the effect of prior therapies on EVE activity demonstrating that EVE improved outcomes regardless of prior treatments. The safety profile of EVE was not impacted by the use of prior lines of therapies and was similar to that reported for the overall population analysis.[@CIT0070]

In addition, limited retrospective studies showed data about sequence of therapies in mixed NET populations, including small number of patients with lung NET.[@CIT0027],[@CIT0032],[@CIT0071],[@CIT0072] Faggiano et al, suggested sequences with first-line SSA followed by SSA high-dose or PRRT as second-line treatment for mixed population NETs. Furthermore chemotherapy and targeted therapy should be then considered in case of further progression because of their worse tolerability.[@CIT0071] Panzuto et al performed a real-world analysis of NET patients treated with EVE suggesting that EVE should be planned before PRRT and chemotherapy to avoid predictable severe toxicities.[@CIT0072]

Finally, the last two retrospective analyses were focused on lung NETs and provided an overview of the real-life clinical practice.[@CIT0027],[@CIT0032] Because of long recruitment period and consequent heterogeneity of patient management, the comparison between treatment strategies is precluded. Of note SSAs were the most commonly performed first-line therapy.

No absolute indication about the EVE timing in lung NET can be drawn from our analysis.

The European medicines agency (EMA) approved EVE in lung NETs with progressive disease without a restriction to a subgroup or a specific line of treatment.

As suggested in the ENETS guidelines EVE may be recommended as a first-line therapy in advanced lung NET with progressive disease. However, in patients with low proliferative activity (G1, typical carcinoid) with strong SSTR expression on imaging, preferably with Ki-67 \<10%, an SSA may be preferred to EVE as first-line therapy ([Table 3](#T0003){ref-type="table"}).

The same guidelines reported that temozolomide-based chemotherapy may be considered in NET G3 and in high-risk pulmonary NET.[@CIT0073]

Special Consideration: Effect on Tumor Shrinkage {#S0004-S2007}
------------------------------------------------

Tumor shrinkage can be a goal in case of future surgical approach or mass-effect symptoms control. Data about tumor shrinkage, in lung NET treated with EVE are reported in [Table 4](#T0004){ref-type="table"}. Everolimus is not considered a strong cytoreductive drug in NETs more in general. Similarly in lung NETs, the reported partial response (PR) rate is very low; however a remarkable percentage of patients treated with EVE achieved some grade of tumor shrinkage, as reported in the waterfall plots.

Special Consideration: EVE ± SSA {#S0004-S2008}
--------------------------------

Octreotide and lanreotide are the only two SSAs usable in clinical practice, also for non-functioning lung NETs. Pasireotide is just investigational.

Provided that in functioning NETs an SSA should be done for syndrome control an open debate remains about the EVE + SSA in non-functioning NETs.

The role of SSA in reducing the expression of insulin-like growth factors (IGF) and epidermal growth factor (EGF) along with EVE suggests the hypothesis that these two drugs work synergistically to arrest cell growth and to control hypersecretory activity in NETs.[@CIT0074] However, despite the strong biological rationale, there are no absolute clinical data to propose the combination of EVE and available SSAs in nonfunctioning lung NETs.

Although the LUNA study showed that EVE + PAS LAR was active and potential effective no practical conclusions can be drawn from that due to the type of study and unfortunately no further investigational plan exists to check the efficacy of this combo in lung NETs.

Special Consideration: EVE in Functioning Lung NETs {#S0004-S2009}
---------------------------------------------------

Although from the analysed studies a clinical impact of EVE + OCT LAR can be supposed also in functioning lung NETs EVE was approved just for non-functioning lung NETs due to the unmet statistical endpoint of the RADIANT-2 trial.

While EVE is utilized in NETs for tumor growth control, recent studies supported its use also for syndrome control in refractory functioning NETs.[@CIT0075],[@CIT0076]

Furthermore it should be considered that in the LUNA trial 23% (n=28) functioning lung and thymus carcinoids were included. Similarly in the ITMO study 26% (n=13) functioning NETs were included and the first-line EVE+OCT LAR combo resulted active regardless of the presence or absence of carcinoid syndrome.

Conclusion {#S0005}
==========

To date no therapy can be considered as a standard of care for patients with an advanced lung NET. Everolimus is the only drug specifically approved for lung NETs, although this approval was based on the positive results of a large-randomised phase III trials including a mixed population of GI and lung NETs and it regarded just the nonfunctioning NETs. SSAs are recommended for functioning lung NETs but they are allowed to be proposed also for non-functioning lung NETs despite they were approved as antiproliferative agents just for GEP NETs. PRRT is investigational for lung NETs whereas it was approved for all GEP NETs. In many Countries temozolomide or other chemotherapeutic agents are allowed to be proposed for lung NETs even without specific evidence and approval. Liver-directed treatments, surgical and not surgical, are usually discussed as in GEP setting, outside specific evidence.

So far no specific sequence or integration of therapies have been validated for advanced lung NETs.

On this basis in clinical practice EVE, the only specifically approved drug for lung NETs, should be managed among this heterogeneous therapeutic landscape. Therefore, it is advisable that each clinical case is discussed within a NET-dedicated multidisciplinary team (MDT) and a therapeutic strategy rather than a single therapy choice is shared. Evidence, guidelines, goals of treatment are all critical factors to be considered to make an adequate clinical decision.

There is evidence to consider EVE as first-line or further-line therapy in nonfunctioning progressive advanced lung NETs. Although there is not evidence against the use of EVE in naïve patients with lung NET however data are more solid for pre-treated patients, mainly with SSA.

Clinical data about a combination of EVE + SSA in non-functioning lung NETs are poor and not solid.

Despite the negative statistical results but apparently positive clinical impact of the RADIANT-2 trial EVE + SSA could be considered in selected cases of advanced functioning lung NETs resistant to SSA, provided that it is allowed by local regulatory authorities.
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[^1]: **Abbreviations:** EVE, everolimus; OCT, Octreotide; NET, neuroendocrine tumor; SSA, somatostatin analogue; PAS, pasireotide.

[^2]: **Abbreviations:** PD, progressive disease; TC, typical carcinoid; AC, atypical carcinoid; NOS, not otherwise specified; PS, performance status; SSA, somatostatin analogue; CgA, plasma chromogranin A; EVE, everolimus; NR, not reported; RT, radiotherapy (can include peptide receptor radionuclide therapy); PAS, pasireotide; OCT, octreotide.

[^3]: **Notes:** \*Response at month 9. \*\*The authors affirmed that subgroup analyses by tumor primary site did not show any significant difference in ORR.

[^4]: **Abbreviations:** DCR, disease control rate (defined as rate of complete, partial and stable responses by radiological assessment, according to criteria employed at the time of the manuscript publication); OCT, octreotide, PAS, pasireotide; PR, partial response; PFS, progression-free survival; HR, hazard ratio; fu, follow-up; EVE, everolimus; NR, not reported.

[^5]: **Abbreviations:** NR, not reported; OCT, octreotide; PAS, pasireotide.
